Eltrombopag for the treatment of immune thrombocytopenia

References

• Rodeghiero F, Stasi R, Gernsheimer T et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura (ITP) of adults and children: report from an International Working Group. Blood113, 2386–2393 (2008).
   PubMed Web of Science ®Google Scholar
• Psaila B, Bussel JB. Immune thrombocytopenic purpura. Hematol. Oncol. Clin. North Am.21, 743–759 (2007).
   PubMed Web of Science ®Google Scholar
• Cohen YC, Djulbegovic B, Shamai-Lubovitz O et al. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch. Intern. Med.160, 1630–1638 (2000).
   PubMed Web of Science ®Google Scholar
• Portielje JE, Westendorp RG, Kluin-Nelemans HC et al. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood97, 2549–2554 (2001).
   PubMed Web of Science ®Google Scholar
• Provan D, Stasi R, Newland AC et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood115, 168–186 (2010).
   PubMed Web of Science ®Google Scholar
• Cines DB, Bussel JB. How I treat idiopathic thrombocytopenic purpura (ITP). Blood106, 2244–2251 (2005).
   PubMed Web of Science ®Google Scholar
• Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N. Engl. J. Med.346, 995–1008 (2002).
   PubMed Web of Science ®Google Scholar
• Godeau B, Provan D, Bussel J. Immune thrombocytopenic purpura in adults. Curr. Opin. Hematol.14, 535–556 (2007).
   PubMed Web of Science ®Google Scholar
• Hoffman R, Zaknoen S, Yang HH et al. An antibody cytotoxic to megakaryocyte progenitor cells in a patient with immune thrombocytopenic purpura. N. Engl. J. Med.312, 1170–1174 (1985).
   PubMed Web of Science ®Google Scholar
• Chang M, Nakagawa PA, Williams SA et al. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood102, 887–895 (2003).
   PubMed Web of Science ®Google Scholar
• Houwerzijl EJ, Blom NR, van der Want JJ et al. Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura. Blood103, 500–506 (2004).
   PubMed Web of Science ®Google Scholar
• McMillan R, Wang L, Tomer A et al. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood103, 1364–1369 (2004).
   PubMed Web of Science ®Google Scholar
• Zhao YQ, Wang QY, Zhai M et al. A multi-center clinical trial of recombinant human thrombopoietin in chronic refractory idiopathic thrombocytopenic purpura. Zhonghua Nei Ke Za Zhi43, 608–610 (2004).
   PubMedGoogle Scholar
• Nomura S, Dan K, Hotta T et al. Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenic purpura. Blood100, 728–730 (2002).
   PubMed Web of Science ®Google Scholar
• Li J, Yang C, Xia Y et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood98, 3241–3248 (2001).
   PubMed Web of Science ®Google Scholar
• Basser RL, O’Flaherty E, Green M et al. Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood99, 2599–2602 (2002).
   PubMed Web of Science ®Google Scholar
• Wang B, Nichol JL, Sullivan JT. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin. Pharmacol. Ther.76, 628–638 (2004).
   PubMed Web of Science ®Google Scholar
• Erickson-Miller CL, DeLorme E, Tian SS et al. Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp. Hematol.33, 85–93 (2005).
   PubMed Web of Science ®Google Scholar
• Erhardt J, Erickson-Miller CL, Tapley P. SB 497115-GR, a low molecular weight TPOR agonist, does not induce platelet activation or enhance agonist-induced platelet aggregation in vitro. Blood104, 59b (2004) (Abstract 3888).
   Web of Science ®Google Scholar
• Jenkins JM, Williams D, Deng Y et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood109, 4739–4741 (2007).
   PubMed Web of Science ®Google Scholar
• Kuter DJ, Bussel JB, Lyons RM et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomized controlled trial. Lancet371, 395–403 (2008).
   PubMed Web of Science ®Google Scholar
• Bussel JB, Cheng G, Saleh MN et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N. Engl. J. Med.357, 2237–2247 (2007).
   PubMed Web of Science ®Google Scholar
• Bussel JB, Provan D, Shamsi T et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet373, 641–648 (2009).
   PubMed Web of Science ®Google Scholar
• Bussel J, Psaila B, Saleh M et al. Efficacy and safety of repeated intermittent treatment with eltrombopag in patients with chronic idiopathic thrombocytopenic purpura. Blood112, 1176 (2008) (Abstract 3431).
   Google Scholar
• Cheng G, Saleh M, Marcher C et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomized Phase 3 study. Lancet377, 393–402 (2011).
   PubMed Web of Science ®Google Scholar
• Saleh M, Cheng G, Bussel J et al. EXTEND study update: safety and efficacy of eltrombopag in adults with chronic immune thrombocytopenia (ITP) from June 2006 to February 2010. Blood166, 36 (2010) (Abstract 67).
   Google Scholar
• Sarpatwari A, Bennett D, Logie JW et al. Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database. Haematologica95, 1167–1175 (2010).
   PubMed Web of Science ®Google Scholar
• Douglas V, Tallman M, Cripe L et al. Thrombopoietin administered during induction chemotherapy to patients with acute myeloid leukemia induces transient morphologic changes that may resemble chronic myeloproliferative disorders. Am. J. Clin. Pathol.117, 844–850 (2002).
   PubMed Web of Science ®Google Scholar
• Bussel J, Kuter D, Pullarkat V et al. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood113, 2161–2171 (2009).
   PubMed Web of Science ®Google Scholar
• Mazzucconi MG, Fazi P, Bernasconi S et al. Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood109, 1401–1407 (2007).
   PubMed Web of Science ®Google Scholar
• Kojouri K, Vesely SK, Terrell DR, George JN. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood104, 2623–2634 (2004).
   PubMed Web of Science ®Google Scholar
• Godeau B, Porcher R, Fain O et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter Phase 2 study. Blood112, 999–1004 (2008).
   PubMed Web of Science ®Google Scholar
• Arnold DM, Dentali F, Crowther MA et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann. Intern. Med.146, 25–33 (2007).
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Fenaux P, Sekeres MA et al. Safety and efficacy of romiplostim in patients with lower risk myelodysplastic syndrome and thrombocytopenia. J. Clin. Oncol.28, 437–444 (2010).
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Dusheiko G, Shiffman ML et al. Eltrombopag for thrombocytopenia in patients with cirrhosisassociate hepatitis C. N. Engl. J. Med.357, 227–236 (2007).
   Google Scholar